SCHEMBL1748256

SCHEMBL1748256

CS(=O)(=O)c1ccc(N2CCNCC2)cc1NCc1cc(Cl)cc(Cl)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 13/20 0.54
ADRA2C P18825 2/20 0.46
ADRA1D P25100 2/20 0.46
ADRA1A P35348 2/20 0.46
ADRA1B P35368 2/20 0.46
ADRB1 P08588 2/20 0.46
CHRM2 P08172 1/20 0.46
CHRM4 P08173 1/20 0.46
CHRM1 P11229 1/20 0.46
CHRM3 P20309 1/20 0.46
GUSB P08236 1/20 0.45
MAPT P10636 3/20 0.45
LMNA P02545 1/20 0.45
POLB P06746 1/20 0.45
RECQL P46063 1/20 0.45
BLM P54132 1/20 0.45
ALDH1A1 P00352 2/20 0.42
HTT P42858 2/20 0.42
GAA P10253 1/20 0.42
HTR3E A5X5Y0 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL1748665 0.99 HTR6 (0.53) HTR6ADRA2CADRA1DADRA1AADRA1B
Tert-Butyl Formate SCHEMBL27915001 0.91 HTR6 (0.49) HTR6ADRA2CADRA1DADRA1AADRA1B
SCHEMBL5021110 0.84 HTR6 (0.52) HTR6GUSBMAPTALDH1A1HTT
SCHEMBL5283022 0.84 MAPT (0.45) HTR6ADRA2CADRA1DADRA1AADRA1B
SCHEMBL1748342 0.80 SMN1; SMN2 (0.52) MAPTLMNAPOLBRECQLBLM
SCHEMBL1747990 0.79 HTR6 (0.68) HTR6ADRB1CHRM2CHRM4CHRM1
Hydrochloric Acid SCHEMBL1748809 0.78 HTR6 (0.67) HTR6ADRB1CHRM2CHRM4CHRM1
SCHEMBL1748540 0.78 HTR6 (0.84) HTR6MAPTLMNAPOLBRECQL
SCHEMBL3929085 0.78 HTR6 (0.64) HTR6GUSB
Hydrochloric Acid SCHEMBL1748572 0.77 HTR6 (0.82) HTR6MAPTLMNAPOLBRECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7968538-B2 Substituted arylamine compounds and methods of treatment GALENEA CORP. (US) 2011-06-28 US claimed
US-20120115850-A1 SUBSTITUTED ARYLAMINE COMPOUNDS AND METHODS OF TREATMENT BECKER OREN (IL) 2012-05-10 US disclosed
US-20120115850-A1 SUBSTITUTED ARYLAMINE COMPOUNDS AND METHODS OF TREATMENT BECKER OREN (IL) 2012-05-10 US disclosed
US-7968538-B2 Substituted arylamine compounds and methods of treatment GALENEA CORP. (US) 2011-06-28 US disclosed
US-7968538-B2 Substituted arylamine compounds and methods of treatment GALENEA CORP. (US) 2011-06-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120115850-A1 SUBSTITUTED ARYLAMINE COMPOUNDS AND METHODS OF TREATMENT HTR6, HTR2A, HTR3B HTR6 1/4885ADRA2C 24/4885ADRA1D 75/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.